Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial - Archive ouverte HAL Access content directly
Journal Articles Haematologica Year : 2015

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

(1, 2) , (1, 2) , (3, 4) , (4) , (4) , (5) , (6) , (7, 8) , (7) , (9) , (10) , (1, 2) , (1, 2) , (7) , (6) , (11) , (5) , (1, 2) , (6, 12, 13)
1
2
3
4
5
6
7
8
9
10
11
12
13
Caroline Régny
  • Function : Author
  • PersonId : 1011519

Abstract

Allogeneic transplantation is a challenge in patients of advanced age because of a high risk of non-relapse mortality and potential long-lasting impairment of health-related quality of life. The development of reduced-intensity conditioning regimens has allowed the use of allogeneic transplantation in this population, but the optimal regimen remains undefined. We conducted a multicenter phase II trial evaluating the safety and efficacy of a reduced-intensity conditioning regimen combining fludarabine, intravenous busulfan, and rabbit antithymocyte globulins in patients older than 55 years of age transplanted from matched-related donor. In addition, health-related quality of life was prospectively measured. Seventy-five patients with a median age of 60 years (range 55-70) were analyzed. Grade III-IV acute and extensive chronic graft-versus-host diseases were found in 3% and 27% of patients, respectively. The day 100 and 1-year non-relapse mortality incidences were 1% and 9%, respectively. The cumulative incidences of relapse, progression-free survival and overall survival at two years were 36%, 51% and 67%, respectively, with a median follow up of 49 months. Global health-related quality of life, physical functioning, emotional functioning, and social functioning were not impaired compared to baseline for more than 75% of the patients (75%, 81.4%, 82.3%, and 75%, respectively). Thirty-four of the 46 (74%) progression-free patients at one year were living without persistent extensive chronic graft-versus-host disease. We conclude that the reduced-intensity conditioning regimen combining fludarabine, intravenous busulfan, and rabbit antithymocyte globulins is well tolerated in patients older than 55 years with low non-relapse mortality and long-term preserved quality of life.
Fichier principal
Vignette du fichier
1000269.pdf (1.94 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-02167058 , version 1 (27-06-2019)

Identifiers

Cite

Didier Blaise, Raynier Devillier, Anne-Gaelle Lecoroller-Sorriano, Jean-Marie Boher, Agnès Boyer-Chammard, et al.. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica, 2015, 100 (2), pp.269-274. ⟨10.3324/haematol.2014.113571⟩. ⟨hal-02167058⟩
70 View
24 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More